Business
Alpha Cognition to Participate in Virtual Fireside Chat Hosted by Titan Partners
VANCOUVER, British Columbia & DALLAS, December 01, 2025--Alpha Cognition Inc. (Nasdaq: ACOG) ("Alpha Cognition" or the "Company"), a commercial-stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases, today announced that Alpha Cognition will participate in an upcoming virtual fireside chat hosted by Boris Peaker of Titan Partners. The discussion will focus on commercialization efforts and research initiatives to accelerate commercial adoption.
About this update from Alpha Cognition Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1402,"height":504,"url":"https://media.zenfs.com/en/business-wire.com/4f920b9cac59bc45c822056deb8e58d6"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/zeJTXfTAm0EwEBfJx4bGtA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTM0NTtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/4f920b9cac59bc45c822056deb8e58d6","width":960,"height":345},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/cKyRQ9_.BBZ2VKjY60J.zw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD04NjI7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/4f920b9cac59bc45c822056deb8e58d6","width":1200,"height":431}},"lazy":false},{"type":"text","content":"VANCOUVER, British Columbia & DALLAS, December 01, 2025--(BUSINESS WIRE)--Alpha Cognition Inc. (Nasdaq: ACOG) ("Alpha Cognition" or the "Company"), a commercial-stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases, today announced that Alpha Cognition will participate in an upcoming virtual fireside chat hosted by Boris Peaker of Titan Partners. The discussion will focus on commercialization efforts and research initiatives to accelerate commercial adoption.","length":528,"tagName":"p"},{"type":"text","content":"Presentation Details: Titan Partners Fireside Chat","length":50,"tagName":"p"},{"type":"text","content":"Date: December 2, 2025Time: 12:00 pm – 1:00 pm ESTParticipant: Michael McFadden, CEOHost: Boris Peaker, Managing Director, Titan PartnersLink to Register: https://us06web.zoom.us/webinar/register/WN_5W_rY9BrSZ2eqv3dp_FqoQ","length":225,"tagName":"p"},{"type":"text","content":"About Alpha Cognition Inc.","length":26,"tagName":"p"},{"type":"text","content":"Alpha Cognition Inc. is a commercial stage, biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer’s disease and cognitive Impairment with mild Traumatic Brain Injury ("mTBI"), for which there are currently no approved treatment options.","length":327,"tagName":"p"},{"type":"text","content":"ALPHA-1062 formulated as a delayed release oral tablet (ZUNVEYL®), is an FDA approved new generation acetylcholinesterase inhibitor for the treatment of Alzheimer’s disease, with expected minimal ...